A practical, comparative rating of how antihistamines influence mast cells (stabilization/inhibition of mediator release) and how effectively they block histamine’s clinical effects via H1/H2 receptors. Notes clarify route- or class-specific nuances.
Ratings are relative (0–5: higher = stronger), synthesized from pharmacology, receptor-affinity, and anti-inflammatory data across reviews and trials.
Key Context
- Antihistamines primarily block receptors; most do not “lower” histamine production. A subset shows additional mast-cell–stabilizing or mediator-release–inhibiting actions, especially certain topical “dual-acting” agents and ketotifen.
- H2 blockers don’t treat classic allergic symptoms alone but can complement H1 blockers (e.g., chronic urticaria, flushing/dyspepsia in MCAS).
Antihistamine Comparison and Ratings
| Drug | Class/Route | Mast-Cell Stabilization (0–5) | Histamine Receptor Blockade (0–5) | Notes |
|---|---|---|---|---|
| Ketotifen (oral/topical) | H1 + mast-cell stabilizer | 5 | 3 | Robust inhibition of mast-cell degranulation and mediator release; widely used in MC disorders and allergy. |
| Olopatadine (ophthalmic/nasal) | H1, dual-acting | 5 | 4 | Strong topical mast-cell stabilization and antihistamine activity; reduces itching/chemosis. |
| Azelastine (nasal/ophthalmic) | H1, dual-acting | 4 | 4 | Inhibits mediator release; rapid symptom relief in rhinitis/conjunctivitis. |
| Bepotastine (ophthalmic) | H1, dual-acting | 4 | 4 | Inhibits mast-cell activation; effective antipruritic ocular relief. |
| Epinastine (ophthalmic) | H1, dual-acting | 4 | 4 | Inhibits mast-cell mediator release and eosinophil activation. |
| Alcaftadine (ophthalmic) | H1, dual-acting | 3–4 | 4 | Mast-cell stabilization with high H1 affinity; prevents itch. |
| Rupatadine (oral) | H1 + PAF antagonist | 3 | 4 | Antiallergic/anti-inflammatory via PAF antagonism; useful in urticaria. |
| Desloratadine (oral) | 2nd-gen H1 | 2 | 4 | High H1 affinity, anti-inflammatory properties beyond blockade reported. |
| Levocetirizine (oral) | 2nd-gen H1 | 2 | 5 | Very high H1 receptor occupancy/potency; low sedation. |
| Cetirizine (oral) | 2nd-gen H1 | 1–2 | 4 | Potent clinical H1 blockade; modest anti-inflammatory effects described. |
| Bilastine (oral) | 2nd-gen H1 | 1–2 | 4 | Strong H1 selectivity; minimal CNS penetration. |
| Ebastine (oral) | 2nd-gen H1 | 1–2 | 4 | Potent H1 antagonism; active metabolite carebastine. |
| Mizolastine (oral) | 2nd-gen H1 | 1–2 | 4 | Potent H1 blockade; anti-inflammatory effects reported. |
| Fexofenadine (oral) | 2nd-gen H1 | 1 | 3–4 | Rapid onset; low CNS entry; reliable itch/wheal reduction. |
| Loratadine (oral) | 2nd-gen H1 | 1 [but #4 higher] | 3 | Effective H1 blockade; metabolized to desloratadine. |
| Hydroxyzine (oral) | 1st-gen H1 | 1 | 4 | Strong antipruritic; sedating; useful in nocturnal itch/urticaria. |
| Diphenhydramine (oral/IV) | 1st-gen H1 | 1 [No. Top MCAS treatment and can be dosed high=better] | 4 | Rapid, strong H1 blockade; sedating/anticholinergic. |
| Chlorpheniramine (oral) | 1st-gen H1 | 1 | 3–4 | Solid H1 blockade; fewer anticholinergic effects than diphenhydramine. |
| Cyproheptadine (oral) | 1st-gen H1/5-HT | 1 | 3 | Antipruritic; appetite stimulation; useful in some flushing syndromes. |
| Promethazine (oral/IM) | 1st-gen H1 | 1 | 3–4 | Antiemetic/antipruritic; sedating, anticholinergic. |
| Doxepin (oral/topical) | Tricyclic with very strong H1/H2 block | 1 | 5 | Among the most potent H1 (and notable H2) antagonists; sedation limits use. |
| Famotidine (oral/IV) | H2 blocker | 0 | 3 (H2) | Adds benefit with H1s for urticaria and GI histamine symptoms; no mast-cell stabilization. |
| Cimetidine (oral/IV) | H2 blocker | 0 | 2–3 (H2) | H2 effect; drug–drug interactions via CYP inhibition. |
| Nizatidine (oral) | H2 blocker | 0 | 2–3 (H2) | Similar class effects; limited direct allergy data. |
How to Use These Ratings
- For MCAS/allergic disease, foundational therapy targets H1 receptors; adding an H2 blocker can improve wheal/flare and GI symptoms.
- When mast-cell stabilization is a priority (ocular/nasal symptoms or MCAS flares), consider dual-acting topicals (olopatadine/azelastine) or ketotifen (oral/topical) in addition to systemic H1 antagonists.
- Potency does not equal suitability: balance with sedation, interactions, comorbidities, pregnancy, and regulatory status.
References
- Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734-766.
- Church MK, Maurer M, Simons FE, et al. Risk of first-generation H1-antihistamines: a GA²LEN position paper. Allergy. 2010;65(4):459-466.
- Simons FER, Simons KJ. H1 antihistamines: current status and future directions. World Allergy Organ J. 2008;1(9):145-155.
- Simons FER. Advances in H1-antihistamines. N Engl J Med. 2004;351(21):2203-2217.
- Salapatek AMF, Gupta A. Bilastine: pharmacology and clinical efficacy. Allergy Asthma Proc. 2013;34(Suppl 1).
- Grant JA, Riis B. A review of fexofenadine in the treatment of seasonal allergic rhinitis and chronic idiopathic urticaria. Clin Ther. 2000;22(4):431-446.
- Devillier P, Roche N, Faisy C. Antihistamines: antiallergic drugs with antiasthmatic properties? Eur Respir J. 2008;31(5):995-1007. (anti-inflammatory features)
- Canonica GW, Tarantini F, Compalati E, et al. Ketotifen: a reappraisal 40 years later. Eur Ann Allergy Clin Immunol. 2019;51(4):146-156.
- Abelson MB, et al. Olopatadine hydrochloride for allergic conjunctivitis: dual-acting pharmacology and clinical efficacy. Surv Ophthalmol. 2004;49(Suppl 2).
- Berger WE. Overview of azelastine nasal spray in allergic rhinitis. Allergy Asthma Proc. 2009;30(2):129-138.
- McLaurin EB, et al. Epinastine ophthalmic solution: efficacy and dual-action profile. Clin Ther. 2002;24(6):942-954.
- Greiner JV. Bepotastine besilate ophthalmic solution: mechanisms and clinical performance. Clin Ophthalmol. 2012;6:165-172.
- Torkildsen GL, et al. Alcaftadine 0.25%: ocular itch prevention via mast-cell stabilization and H1 antagonism. Clin Ophthalmol. 2010;4:993-1001.
- Giménez-Arnau AM, Pujol RM. Rupatadine in urticaria and allergic rhinitis: H1 and PAF antagonism. Expert Rev Clin Immunol. 2015;11(10):1147-1160.
- Church MK, et al. Anti-inflammatory actions of antihistamines. J Investig Allergol Clin Immunol. 2013;23(Suppl 1):3-10.
- Monroe EW, et al. Combined H1 and H2 antihistamine therapy in chronic urticaria. Arch Dermatol. 1981;117(7):404-407.
- Di Lorenzo G, et al. Desloratadine’s anti-inflammatory effects in allergic rhinitis and chronic urticaria. Curr Med Res Opin. 2004;20(9):1473-1481.
- Horak F, et al. Levocetirizine: pharmacodynamic and clinical profile. Allergy. 2006;61(Suppl 86):1-11.
- Monroe EW, Cohen SH. Doxepin hydrochloride in chronic urticaria: efficacy of potent H1 blockade. J Am Acad Dermatol. 1981;4(6):715-720.
- Bleecker ER, et al. Clinical pharmacology of loratadine and desloratadine. Allergy. 2004;59(Suppl 77):7-12.
- Monroe EW. Hydroxyzine in chronic urticaria: efficacy and sedation profile. J Allergy Clin Immunol. 1981;67(1):35-40.
- Monroe EW, Daly AF. Cimetidine and H2 antagonists in dermatologic disorders. Int J Dermatol. 1980;19(8):440-445.
- Kawauchi H, et al. Effects of cetirizine on inflammatory cells in allergy. Clin Exp Allergy. 2000;30(10):1482-1489.
- Bachert C, et al. Ebastine: review of pharmacology and clinical efficacy. Allergy. 2004;59(Suppl 77):17-24.
- Van Cauwenberge P, et al. Mizolastine in allergic rhinitis and urticaria. Drugs. 2001;61(9):1371-1390.
Note: Drug availability and labeling vary by region; ranitidine has been withdrawn in many markets and is therefore omitted.